{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:11:15Z","timestamp":1765728675252,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Institutional Development Support Program of the National Health System (Proadi-SUS) and Hospital Alem\u00e3o Oswaldo Cruz","award":["01\/2017"],"award-info":[{"award-number":["01\/2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40263-018-0541-5","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T04:08:02Z","timestamp":1531714082000},"page":"813-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Disease-Modifying Therapies for Relapsing\u2013Remitting Multiple Sclerosis: A Network Meta-Analysis"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-1320","authenticated-orcid":false,"given":"Rosa C.","family":"Lucchetta","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-584X","authenticated-orcid":false,"given":"Helena H. L.","family":"Borba","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-3120","authenticated-orcid":false,"given":"Let\u00edcia P.","family":"Leonart","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-2995","authenticated-orcid":false,"given":"Vinicius L.","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1495-4801","authenticated-orcid":false,"given":"Aline F.","family":"Bonetti","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-2002","authenticated-orcid":false,"given":"Bruno S.","family":"Riveros","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-3620","authenticated-orcid":false,"given":"Jefferson","family":"Becker","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-9595","authenticated-orcid":false,"given":"Fernando","family":"Fernandez-Llim\u00f3s","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-4044","authenticated-orcid":false,"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"541_CR1","unstructured":"Multiple Sclerosis International Federation. Atlas of MS 2013. Mapping multiple sclerosis around the world. 2014.\u00a0\nhttp:\/\/www.msif.org\/wp-content\/uploads\/2014\/09\/Atlas-of-MS.pdf\n\n. Accessed 11 July 2018."},{"key":"541_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018;24:96\u2013120. \nhttps:\/\/doi.org\/10.1177\/1352458517751049\n\n.","journal-title":"Mult Scler J."},{"key":"541_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278\u201386.","journal-title":"Neurology."},{"key":"541_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-9-1","volume":"9","author":"M Pickin","year":"2009","unstructured":"Pickin M, Cooper CL, Chater T, O\u2019Hagan A, Abrams KR, Cooper NJ, et al. The multiple sclerosis risk sharing scheme monitoring study\u2014early results and lessons for the future. BMC Neurol BioMed Cent. 2009;9:1.","journal-title":"BMC Neurol BioMed Cent."},{"key":"541_CR5","volume-title":"Harrisons manual of medicine","author":"DL Kasper","year":"2016","unstructured":"Kasper DL, Fauci AS, Hauser S, Longo D, Jameson JL, Loscalzo J. Harrisons manual of medicine. 19th ed. New York City: McGraw-Hill Education; 2016.","edition":"19"},{"key":"541_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/pgmj.2004.029413","volume":"81","author":"SM Leary","year":"2005","unstructured":"Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. The Fellowship of Postgraduate Medicine. Postgrad Med J. 2005;81:302\u20138.","journal-title":"Postgrad Med J"},{"key":"541_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273\u20139. \nhttps:\/\/doi.org\/10.1136\/practneurol-2015-001139\n\n.","journal-title":"Pract Neurol."},{"key":"541_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub2","author":"I Tramacere","year":"2015","unstructured":"Tramacere I, Del Giovane C, Salanti G, D\u2019Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane database Syst Rev. \nhttps:\/\/doi.org\/10.1002\/14651858.CD011381.pub2\n\n.","journal-title":"Cochrane database Syst Rev."},{"key":"541_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Heal. 2011;14:429\u201337. \nhttps:\/\/doi.org\/10.1016\/j.jval.2011.01.011\n\n.","journal-title":"Value Heal."},{"key":"541_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","volume":"15","author":"FS Tonin","year":"2017","unstructured":"Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). 2017;15:943.","journal-title":"Pharm Pract (Granada)."},{"key":"541_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med."},{"key":"541_CR12","unstructured":"Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011."},{"key":"541_CR13","unstructured":"Lucchetta RC, Tonin FS, Borba HHL, Leonart LP, Ferreira VL, Bonetti AF, et al. Systematic review and network meta-analysis of disease-modifying therapies in relapsing-remitting multiple sclerosis\u2014CRD42017059120. PROSPERO. 2017.\u00a0\nhttp:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42017059120\n\n. Accessed 11 July 2018."},{"key":"541_CR14","unstructured":"Higgins J, Sterne J, Savovi\u0107 J, Page M, Hr\u00f3bjartsson A, Boutron I, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V (eds) Cochrane Methods Cochrane Database Syst Rev. 2016;Suppl.1."},{"key":"541_CR15","unstructured":"Team RC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.\u00a0\nhttps:\/\/www.r-project.org\/\n\n. Accessed 11 July 2018."},{"key":"541_CR16","unstructured":"Wickham H, Hester J, Fran\u00e7ois R. Readr: Read rectangular tet data. R package version 1.1.1. 2017.\u00a0\nhttps:\/\/cran.r-project.org\/package=readr\n\n. Accessed 11 July 2018."},{"key":"541_CR17","first-page":"40","volume":"7","author":"G Schwarzer","year":"2007","unstructured":"Schwarzer G. Meta: An R package for meta-analysis. R News. 2007;7:40\u20135.","journal-title":"R News."},{"key":"541_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw."},{"key":"541_CR19","unstructured":"Valkenhoef G van, Kuiper J. GeMTC: Network Meta-Analysis Using Bayesian Methods. R Packag version 08-2. 2016. \nhttps:\/\/cran.r-project.org\/package=gemtc\n\n. Accessed 11 July 2018."},{"key":"541_CR20","unstructured":"Plummer M. RJags: Bayesian Graphical Models using MCMC. R Packag version 4-6. 2016. \nhttps:\/\/cran.r-project.org\/package=rjags\n\n. Accessed 11 July 2018."},{"key":"541_CR21","first-page":"7","volume":"6","author":"M Plummer","year":"2006","unstructured":"Plummer M, Best N, Cowles K, Vines K. CODA: convergence diagnosis and output analysis for MCMC. R News. 2006;6:7\u201311.","journal-title":"R News."},{"key":"541_CR22","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105\u201324. \nhttps:\/\/doi.org\/10.1002\/sim.1875\n\n.","journal-title":"Stat Med."},{"key":"541_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41:818\u201327. \nhttps:\/\/doi.org\/10.1093\/ije\/dys041\n\n.","journal-title":"Int J Epidemiol."},{"key":"541_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33:641\u201356. \nhttps:\/\/doi.org\/10.1177\/0272989X12455847\n\n.","journal-title":"Med Decis Making."},{"key":"541_CR25","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"GRADE Working Group","year":"2004","unstructured":"GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490. \nhttps:\/\/doi.org\/10.1136\/bmj.328.7454.1490\n\n.","journal-title":"BMJ."},{"key":"541_CR26","doi-asserted-by":"crossref","unstructured":"Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (London, England). 2002;359:1453\u201360.","DOI":"10.1016\/S0140-6736(02)08430-1"},{"key":"541_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","volume":"9","author":"E Fogarty","year":"2016","unstructured":"Fogarty E, Schmitz S, Tubridy N, Walsh C. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Mult Scler Relat Disord 2016;9:23\u201330. \nhttps:\/\/doi.org\/10.1016\/j.msard.2016.06.001\n\n.","journal-title":"Mult Scler Relat Disord"},{"key":"541_CR28","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","volume":"34","author":"MK Siddiqui","year":"2017","unstructured":"Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing\u2013remitting multiple sclerosis. Curr Med Res Opin. 2017;34:1361\u201371. \nhttps:\/\/doi.org\/10.1080\/03007995.2017.1407303\n\n.","journal-title":"Curr Med Res Opin."},{"key":"541_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.14740\/jocmr3168w","volume":"10","author":"V Hamidi","year":"2018","unstructured":"Hamidi V, Couto E, Ringerike T, Klemp M. A multiple treatment comparison of eleven disease-modifying drugs used for multiple sclerosis. J Clin Med Res. 2018;10:88\u2013105.","journal-title":"J Clin Med Res."},{"key":"541_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/1756285617722706","volume":"10","author":"T Ziemssen","year":"2017","unstructured":"Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017;10:343\u201359. \nhttps:\/\/doi.org\/10.1177\/1756285617722706\n\n.","journal-title":"Ther Adv Neurol Disord."},{"key":"541_CR31","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1080\/13696998.2017.1355310","volume":"20","author":"H Yang","year":"2017","unstructured":"Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J Med Econ. 2017;20:1056\u201365. \nhttps:\/\/doi.org\/10.1080\/13696998.2017.1355310\n\n.","journal-title":"J Med Econ."},{"key":"541_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0149-2918(03)90013-0","volume":"25","author":"T Vartanian","year":"2003","unstructured":"Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003; 25:105\u201318.","journal-title":"Clin Ther [Internet]."},{"key":"541_CR33","doi-asserted-by":"publisher","first-page":"e0127960","DOI":"10.1371\/journal.pone.0127960","volume":"10","author":"K Tolley","year":"2015","unstructured":"Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One. 2015;10:e0127960.","journal-title":"PLoS One."},{"key":"541_CR34","doi-asserted-by":"publisher","first-page":"e1548","DOI":"10.1212\/WNL.0000000000005422","volume":"90","author":"D Croteau","year":"2018","unstructured":"Croteau D, Flowers C, Kulick CG, Brinker A, Kortepeter CM, Croteau C, Kulick CG, Brinker A, Kortepeter CMDF, et al. Acute acalculous cholecystitis: a new safety risk for patients with MS treated with alemtuzumab. Neurology. 2018;90:e1548\u201352. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000005422\n\n.","journal-title":"Neurology."},{"key":"541_CR35","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"JA Coles","year":"2017","unstructured":"Coles JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DAJC. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89:1117\u201326.","journal-title":"Neurology."},{"key":"541_CR36","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/14740338.2017.1346082","volume":"16","author":"CA Clerico","year":"2017","unstructured":"Clerico CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli LMA. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2017;16:963\u201372.","journal-title":"Expert Opin Drug Saf."},{"key":"541_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/14740338.2017.1250881","volume":"16","author":"BP McGinley","year":"2017","unstructured":"McGinley BP, Cohen JAMPM. Safety of monoclonal antibodies for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2017;16:89\u2013100.","journal-title":"Expert Opin Drug Saf."},{"key":"541_CR38","unstructured":"Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA\u00ae (daclizumab) for Relapsing Multiple Sclerosis. 2018. \nhttps:\/\/www.businesswire.com\/news\/home\/20180302005168\/en\/Biogenand-AbbVie-Announcethe-VoluntaryWorldwide-Withdrawal-Marketing-Authorizations\n\n. Accessed 11 July 2018."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0541-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0541-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0541-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T14:36:36Z","timestamp":1604068596000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0541-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0541-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"16 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by the Institutional Development Support Program of the National Health System (Proadi-SUS) and Hospital Alem\u00e3o Oswaldo Cruz (Grant number 01\/2017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Bruno Riveros and Rosa Lucchetta report personal fees from Biogen and Roche; and Jefferson Becker reports grants and personal fees from Biogen, Novartis, Roche and Teva and personal fees from Bayer, Ipsen, Merck Serono, Sanofi, outside the submitted work. Fernanda Tonin, Helena Borba, Let\u00edcia Leonart, Vin\u00edcius Ferreira, Aline Bonetti, Roberto Pontarolo, Fernando Fernandez-Llim\u00f3s and Astrid Wiens declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}